【摘要】 目的 探讨卡瑞丽珠单抗联合肝动脉化疗栓塞(TACE)在中晚期肝癌患者中的应用效果。方法 回顾性分析2023年1月至2024年11月南阳市中心医院收治的113例中晚期肝癌患者的临床资料。按治疗方法不同分为对照组(n=56)与观察组(n=57)。对照组予以TACE治疗，观察组在此基础上予以卡瑞利珠单抗治疗。比较两组临床疗效、血清T淋巴亚群、肝功能指标[总胆红素(TBiL)、天冬氨酸氨基转移酶(GOT)、丙氨酸氨基转移酶(GPT)]及不良反应。结果 观察组客观缓解率(54.39%)及疾病控制率(85.96%)均高于对照组(35.71%、67.86%),差异有统计学意义(P>0.05)。治疗后，观察组CD3~+水平[(68.27±3.47)%]、CD4~+水平[(38.67±2.15)%]及CD4~+/CD8~+水平(1.54±0.23)均高于对照组[(63.54±3.53)%、(34.33±2.77)%、(1.29±0.26)],CD8~+水平[(25.07±3.65)%]低于对照组[(26.51±3.98)%],TBiL水平[(18.35±5.53)μmol/L]、GOT水平[(53.78±17.06)U/L]及GPT水平[(47.25±6.14)U/L]均低于对照组[(21.02±6.33)μmol/L、(60.56±18.28)U/L、(54.47±7.66)U/L],差异有统计学意义(P<0.05)。两组不良反应发生率比较，差异未见统计学意义(P>0.05)。结论 卡瑞利珠单抗联合TACE对中晚期肝癌患者的治疗效果确切，可有效调节血清T淋巴亚群水平，增强机体免疫功能及肝功能，且较为安全。更多还原

【Abstract】 Objective To investigate the effect of camrelizumab combined with hepatic arterial chemoembolization(TACE) on patients with advanced liver cancer. Methods The clinical data of 113 patients with advanced liver cancer admitted in Nanyang Central Hospital from January 2023 to November 2024 were retrospectively analyzed. They were divided into control group(n=56) and observation group(n=57) according to different treatment methods. The control group was treated with TACE, and the observation group was treated with camrelizumab on the basis of the control group. The clinical efficacy, serum T lymphosubsets, liver function indexes [total bilirubin(TBiL), aspartate aminotransferase(GOT), alanine aminotransferase(GPT)] and adverse reactions were compared between the two groups. Results The objective response rate(54.39%) and disease control rate(85.96%) in the observation group were higher than those in the control group(35.71% and 67.86%), and the differences were significant(P>0.05). After treatment, the levels of CD3~+[(68.27±3.47)%], CD4~+[(38.67±2.15)%] and CD4~+/CD8~+(1.54±0.23) in the observation group were all higher than those in the control group [(63.54±3.53)%,(34.33±2.77)%,(1.29±0.26)], while the level of CD8~+[(25.07±3.65)%] was lower than that in the control group [(26.51±3.98)%], and the levels of TBiL[(18.35±5.53)μmol/L], GOT [(53.78±17.06) U/L] and GPT[(47.25±6.14) U/L] were lower than those in the control group [(21.02±6.33) μmol/L,(60.56±18.28) U/L,(54.47±7.66) U/L], and the differences were significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions Camrelizumab combined with TACE has a definite therapeutic effect on patients with advanced liver cancer, and can effectively regulate the level of serum T lymphosubsets, enhance immune function and liver function, and is relatively safe.更多还原